Key Highlights
- MSB shares rose 3.23% to AUD 2.24 on 16 April 2026, extending a robust 10.34% five-day rally.
- The stock’s upward momentum is driven by the 7 April update confirming Ryoncil net sales reached US$30.3 million for the March quarter, despite typical January seasonality.
- Cumulative revenue since the April 2025 launch is now approaching the US$100 million milestone.
- Mesoblast reported a significant narrowing of losses in H1 FY26, with total revenue jumping to US$51.3 million from just US130 million
- a new US$125 million credit facility, Mesoblast is well-funded to advance its Phase 3 programs in chronic low back pain and life-cycle extensions.
Mesoblast Limited (ASX:MSB)…
